Optimizing the best pharmaceutical agent while minimizing adverse effects is paramount in patients with cancer-associated venous thromboembolism.
Shyam Gelot, PharmD, BCPS
Advertisement
Articles by Shyam Gelot, PharmD, BCPS
Advertisement
Latest Updated Articles
Apixaban: A New Treatment Option for Cancer-Associated VTEPublished: September 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
Regular Melatonin Supplementation May Hide Hidden Heart Complications
3
Early Detection of Type 1 Diabetes: The Power of Screening and Preparation
4
COVID-19 During Pregnancy Raises Neurodevelopmental Risks in Children
5
